腾盛博药-B(02137.HK)今日盘中股价大跌5.48%，引起了市场的广泛关注。
消息面上，公司于前一交易日盘后公布了2025年度业绩。数据显示，公司全年收入仅为1,861万元人民币，虽然亏损较上年同期的5.08亿元收窄至2.23亿元，每股亏损31分，且不派息，但整体业绩表现仍显疲弱。
分析人士认为，尽管亏损有所收窄，但公司收入规模过小且持续处于亏损状态，可能未能达到市场预期，从而引发了投资者的担忧和抛售。
腾盛博药-B(02137.HK)今日盘中股价大跌5.48%，引起了市场的广泛关注。
消息面上，公司于前一交易日盘后公布了2025年度业绩。数据显示，公司全年收入仅为1,861万元人民币，虽然亏损较上年同期的5.08亿元收窄至2.23亿元，每股亏损31分，且不派息，但整体业绩表现仍显疲弱。
分析人士认为，尽管亏损有所收窄，但公司收入规模过小且持续处于亏损状态，可能未能达到市场预期，从而引发了投资者的担忧和抛售。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.